Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb and 360Dx.
The system incorporates robotics from Hamilton and thermal cycling from Bio-Rad Laboratories, and is scheduled to launch early next year.
As the pandemic continues to play out, test developers aren't sure how it will impact STIs and their work around developing and manufacturing tests.
Seattle-based ID Genomics is partnering with a diagnostics instrument developer to adapt its genetic fingerprinting methods for point-of-care use.
The firm is now moving forward on COVID-19 molecular diagnostic clinical trials in the US with the hopes of obtaining FDA Emergency Use Authorization.
Developed by researchers at the National Institutes of Health, the method could reduce the cost of sample prep by a factor of eight.
With a throughput of 150,000 tests per day on a single system, the workflow is now in use in a so-called megalab in the UK.
The firm received clearance and CLIA waiver for a 30-minute point-of-care PCR assay for three common STIs earlier this week.
The firm is investing its COVID testing revenues to expand its oncology offerings through acquisitions and partnerships.
A home-collected dry swab protocol showed 100 percent sensitivity and 99.4 percent specificity versus extraction-based RT-qPCR.
The fever sample collection is an extension of an offering from FIND allowing diagnostics developers to access carefully curated sample collections.